GID BIO
Louisville, US · Delaware corporation
GID BIO develops investigational adipose-derived cell therapies and device platforms aimed at offering physicians and patients alternatives between short-term relief and major surgery. The company operates in the regenerative medicine and medical device space.
Founders & leadership
JW
J. William FutrellFounder, Board of Directors
WW
William W CiminioCo-founder
DS
David SpringerFounder, Board of Directors
DS
David S SmithExecutive
DZ
Dwight ZurawskiChief Financial Officer
WC
William CiminoNamed on SEC filing
NP
Nicholas PachudaNamed on SEC filing
WF
William FutrellNamed on SEC filing
MS
Morgan St. JohnNamed on SEC filing
JM
John MarousNamed on SEC filing
RB
Roy BostockNamed on SEC filing
AK
Adam KatzFounder, Board of Directors
Reported raises · per SEC filings
Form D private placements$7.5M disclosed across 2 rounds · 2013–2021
▶$5.3MraisedJan 2022 · 27 investors · Other Health CareRule 506(b)
▶$5.3MraisedJan 2022 · 27 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- William CiminoExecutive Officer, Director
- Nicholas PachudaDirector
- William FutrellDirector
- Morgan St. JohnDirector
- John MarousDirector
- Roy BostockDirector
- Adam KatzDirector
- David S. SmithExecutive Officer
- Amount sold
- $5.3M
- Minimum investment
- $50K
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.2MraisedJan 2014 · 18 investors · Other Health CareRule 506(b)
▶$2.2MraisedJan 2014 · 18 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jesse SheffermanDirector
- David S SmithExecutive Officer
- J. William FutrellExecutive Officer, Director
- Carlos PellasDirector
- Morgan St. JohnDirector
- William W CiminioExecutive Officer, Director
- Adam KatzDirector
- Ruben DiazDirector
- Offering amount
- $3M
- Amount sold
- $2.2M
- Minimum investment
- $25K
- First sale
- Dec 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 7
by search overlapGate Bio7 shared keywordsGate Bioscience develops small molecule therapeutics called Molecular Gates for disease treatment. The company operates in the drug discovery and development space.
GentiBio7 shared keywordsGentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases. The company builds autologous and allogeneic Treg platforms as an alternative to systemic immune-suppressive therapies.
Ligo Biosciences4 shared keywordsLigo develops computational tools for enzyme design by combining large language models with specialized neural networks to enable scientists and AI agents to discover new enzymes and biological functions.
Bioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Forge Biologics4 shared keywordsForge Biologics is a US-based gene therapy CDMO (contract development and manufacturing organization) offering AAV manufacturing services, technologies, and infrastructure. It supports gene therapy developers across early development, clinical trials, and commercial production, and is a subsidiary of the Ajinomoto Group.
Engage Bio4 shared keywordsEngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.
Gain Therapeutics4 shared keywordsGain Therapeutics develops small molecule drugs for neurodegenerative diseases using an AI-powered drug discovery platform that identifies novel binding sites on disease-related proteins. The company's lead candidate, rexaceract, targets GBA-Parkinson's disease and is in Phase I clinical trials.
Companies competing with GID BIO for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does GID BIO do?
- GID BIO develops investigational adipose-derived cell therapies and device platforms aimed at offering physicians and patients alternatives between short-term relief and major surgery. The company operates in the regenerative medicine and medical device space.
- Who founded GID BIO?
- GID BIO was founded by J. William Futrell, William W Ciminio, David Springer.
- How much funding has GID BIO raised?
- GID BIO has disclosed $7.5M raised across 2 rounds.
- Where is GID BIO headquartered?
- GID BIO is headquartered in Louisville, US.